JPEO

The Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense – Enabling Biotechnologies (JPEO-CBRND-EB) has released a Request for Information (RFI) on New Approach Methods (NAMs) to support medical countermeasure (MCM) development against chemical, biological, radiological, and nuclear (CBRN) threats. In line with broader efforts at the Food and Drug Administration (FDA) and

The Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense (JPEO-CBRND) has released a new Request for Information (RFI) focused on advancing wearable Chem-Bio-Radiological-Nuclear (CBRN) monitoring technologies. As the Department of Defense (DoD) continues strengthening preparedness for complex, multi-domain threats, this RFI seeks industry input on next-generation wearable sensors capable of supporting warfighter

The Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense (JPEO-CBRND) has released a new Request for Information (RFI) titled “End-to-End Untargeted Genomic Sequencing Workflows Appropriate for Military Use.” This RFI underscores the Department of Defense’s (DoD) growing emphasis on rapid, field-deployable biological threat detection, a critical component of maintaining operational readiness in

The Medical CBRN Defense Consortium (MCDC), in collaboration with the Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense (JPEO-CBRND), has released a Request for Information (RFI) to assess industry capabilities in developing broad spectrum prophylactic medical countermeasures (MCMs) against acetylcholinesterase (AChE) inhibitors. These inhibitors, chemical agents that can severely impair nervous system